A Phase II Study of BIBF 1120 (Nintedanib) for Recurrent Malignant Pleural Mesothelioma

Full Title

A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma

Purpose

Malignant pleural mesothelioma is a challenging cancer to treat and often comes back despite therapy. In this study, researchers are evaluating the safety and effectiveness of the investigational drug nintedanib in patients with inoperable malignant pleural mesothelioma that has come back after prior treatment.

Nintedanib inhibits the development of the blood vessels that tumors need to grow and spread. It blocks the activity of three enzymes needed for this process. Nintedanib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable malignant pleural mesothelioma that has come back despite previous chemotherapy that included platinum.
  • Patients may have had up to two prior regimens of chemotherapy.
  • At least 4 weeks must pass between the completion of prior therapies and entry into the study.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Marjorie Zauderer at 646-888-4656.

Protocol

16-608

Phase

II

Investigator

Co-Investigators

Diseases